These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3617239)

  • 1. Serum prolactin assays have no prognostic value in treatment of prostatic cancer by orchidectomy or estrogens.
    Stege R; Carlström K; Eriksson A; Gustafsson SA; Henriksson P; Pousette A
    Urol Int; 1987; 42(2):124-6. PubMed ID: 3617239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of serum hormone concentrations in prostatic cancer.
    Eriksson A; Carlström K
    Prostate; 1988; 13(3):249-56. PubMed ID: 3211806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenocortical function in prostatic cancer patients: effects of orchidectomy or different modes of estrogen treatment on basal steroid levels and on the response to exogenous adrenocorticotropic hormone.
    Carlström K; Stege R
    Urol Int; 1990; 45(3):160-3. PubMed ID: 2161578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment hormone levels in prostatic cancer.
    Haapiainen R; Rannikko S; Alfthan O; Adlercreutz H
    Scand J Urol Nephrol Suppl; 1988; 110():137-43. PubMed ID: 3187401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma.
    Carlström K; Stege R; Henriksson P; Grande M; Gunnarsson PO; Pousette A
    Prostate; 1997 May; 31(3):193-7. PubMed ID: 9167772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
    Stege R; Grande M; Carlström K; Tribukait B; Pousette A
    Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens.
    Eriksson S; Eriksson A; Stege R; Carlström K
    Calcif Tissue Int; 1995 Aug; 57(2):97-9. PubMed ID: 7584882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal pattern in prostatic cancer. II. Correlation with primary response to endocrine treatment.
    Adlercreutz H; Rannikko S; Kairento AL; Karonen SL
    Acta Endocrinol (Copenh); 1981 Dec; 98(4):634-40. PubMed ID: 7304086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of endocrine and radiation therapy in locally advanced prostatic cancer.
    Aro J; Haapiainen R; Kajanti M; Rannikko S; Alfthan O
    Eur Urol; 1988; 15(3-4):182-6. PubMed ID: 3063541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some effects of orchiectomy, oestrogen treatment and radiation therapy in patients with prostatic carcinoma.
    Tomić R
    Scand J Urol Nephrol Suppl; 1983; 77():1-37. PubMed ID: 6426040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurements of prolactin and androgens in patients with prostatic diseases.
    Saroff J; Kirdani RY; Chu TM; Wajsman Z; Murphy GP
    Oncology; 1980; 37(1):46-52. PubMed ID: 6153126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males.
    Berglund L; Carlström K; Stege R; Gottlieb C; Eriksson M; Angelin B; Henriksson P
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2633-7. PubMed ID: 8675589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma.
    Henriksson P; Angelin B; Berglund L
    J Clin Invest; 1992 Apr; 89(4):1166-71. PubMed ID: 1532586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The prognostic significance of prolactin in prostate cancer].
    Røhl HF; Andersen OP
    Ugeskr Laeger; 1987 Dec; 149(50):3402-3. PubMed ID: 3433541
    [No Abstract]   [Full Text] [Related]  

  • 15. Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer.
    Lissoni P; Bignami A; Frontini L; Manganini V; Dapretto E; Gardani GS; Viganò P; Strada G
    Int J Biol Markers; 2005; 20(2):123-5. PubMed ID: 16011043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of orchidectomy performed after cessation of estrogen therapy on serum testosterone concentrations in patients with prostatic carcinoma.
    Tomić R; Damber JE
    Urol Int; 1987; 42(6):441-4. PubMed ID: 3129850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early results of the Finnish Multicentre Study of Prostatic Cancer (Finnprostate).
    Haapiainen R; Rannikko S; Ruutu M; Ala-Opas M; Aro J; Ervasti J; Hansson E; Hurme K; Juusela H; Mäkinen J
    Ann Chir Gynaecol; 1985; 74(6):277-83. PubMed ID: 4096480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen.
    Henriksson P; Johansson SE
    Am J Epidemiol; 1987 Jun; 125(6):970-8. PubMed ID: 3578255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orchiectomy, estrogen therapy and radiotherapy in locally advanced (T3-4 M0) prostatic cancer.
    Aro J; Haapiainen R; Kajanti M; Rannikko S; Alfthan O
    Scand J Urol Nephrol Suppl; 1988; 110():103-7. PubMed ID: 3187397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population.
    Aro J
    Prostate; 1991; 18(2):131-7. PubMed ID: 2006119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.